Misplaced Pages

A therapeutic vaccine is a vaccine which is administered after a disease or infection has already occurred. A therapeutic vaccine works by activating the immune system of a patient to fight an infection. A therapeutic vaccine differs from a prophylactic vaccine in that prophylactic vaccines are administered to individuals as a precautionary measure to avoid the infection or disease while therapeutic vaccines are administered after the individual is already affected by the disease or infection. A therapeutic vaccine fights an existing infection in the body rather than immunizing the body for protection against future diseases and infections. Therapeutic vaccines are mostly used against viral infections. Patients affected with chronic viral infections are administered with therapeutic vaccines, as their immune system is not able to produce enough efficient antibodies.

Provenge, developed by Dendreon, was the first therapeutic vaccine approved by the FDA in 2010. This therapeutic vaccine helped in treating prostate cancer where patients' own white blood cells (WBCs) were taken and treated with drug (vaccine) to train them to differentiate and fight cancer cells.

Functionality

Therapeutic vaccines are a new form of vaccines that are mostly being used for viral infections and various types of cancers. A therapeutic vaccine helps an immune system to recognise a foreign agent such as cancerous cells or a virus. The specific type of therapeutic vaccines include antigen vaccines. In case of antigen vaccines, the body is introduced to a foreign agent to activate the immune system so that it recognizes the agent when later encountered.

Types

There are two types of therapeutic vaccines:

Autologous vaccines

Autologous means 'derived from oneself' – an autologous vaccine is a personalized vaccine which is made from an individual's own cells which could be either cancer cells or immune system cells.

Allogeneic vaccines

Allo means 'other'. Allogeneic vaccines are primarily cancer vaccines which are made from a different individual's cancer cells which are grown in a lab.

How therapeutic vaccines differ from prophylactic vaccines

The concept of therapeutic vaccines is different. When a person hears the word vaccine, the thought of prevention against a certain disease comes to mind. However, therapeutic vaccines are a method of treatment. Like any other vaccine, the immune system is regulated against a specific type of target. The main goal is to enhance the immune system activity. This type of vaccine can be employed for the treatment of various type of diseases and viral infections. Efforts are being made to develop vaccines against various fatal diseases such as HIV, cancer, dengue fever, cholera, Diphtheria, etc.

Therapeutic vaccines against HIV

HIV has no vaccine up until now, but therapeutic vaccines could be the breakthrough for HIV. Such vaccines would enhance affected patients immune systems to fight the disease. Many researchers are trying to develop and test therapeutic HIV vaccines in order to slow the HIV progression to AIDS. People affected with HIV normally have HIV at undetectable level, which is detected by use of antiretroviral therapy (ART). If therapeutic vaccines for HIV work out, many lives will be saved. Many clinical trials are being conducted for HIV therapeutic vaccines, such as those conducted by AIDSinfo, summaries for their trials are available at their website.

Therapeutic vaccine against cancer

Cancer is the major cause of deaths in the recent era. Cancer types and stages have enhanced with time and so has efforts to treat cancer. Currently, there are about 369 cancer vaccine studies ongoing all around the world.

There are three cancer therapeutic vaccines which are approved by USA Food and Drug Administration, as following;

Provenge is Sipuleucel-T, a dendritic cell based vaccine for prostate cancer. Bacillus Calmettle-Guerin (TheraCys) is a live attenuated vaccine which makes use of Mycobacterium bovis strain for bladder invasive cancer. Talimogene laherparepvec (T-VEC or Imlygic) is a vaccine for advanced oncolytic melanoma

References

1. "Preventive vaccine vs therapeutic vaccine | Fondation québecoise du Sida". Archived from the original on 2019-11-10. Retrieved 2019-11-10.
2. Shimasaki, Craig (2014). "Understanding Biotechnology Product Sectors". Biotechnology Entrepreneurship. pp. 113–138. doi:10.1016/B978-0-12-404730-3.00009-9. ISBN 9780124047303. S2CID 107391475.
3. Gulley, James (2012). "Therapeutic vaccines The ultimate personalized therapy?". Human Vaccines & Immunotherapeutics. 9 (1): 219–221. doi:10.4161/hv.22106. PMC 3667942. PMID 22995839.
4. Madan RA, Gulley JL, Fojo T, Dahut WL (2010). "Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression". Oncologist. 15 (9): 969–975. doi:10.1634/theoncologist.2010-0129. PMC 3228037. PMID 20798195.{{cite journal}}: CS1 maint: multiple names: authors list (link)
5. Sondak, Vernon K.; Sabel, Michael S.; Mulé, James J. (1 April 2006). "Allogeneic and Autologous Melanoma Vaccines: Where Have We Been and Where Are We Going?". Clinical Cancer Research. 12 (7): 2337s–2341s. doi:10.1158/1078-0432.CCR-05-2555. hdl:2027.42/39209. PMID 16609055.
6. Hanna, Michael G. (27 October 2014). "Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer". Human Vaccines & Immunotherapeutics. 8 (8): 1156–1160. doi:10.4161/hv.20740. PMC 3551893. PMID 22854664.
7. Griffin, R. Morgan (2006). "Treating Disease With Vaccines". WebMD. Archived from the original on 2021-11-01. Retrieved 2021-04-21.
8. Dr. James W. Hodge, Dr. Chandan Guha, Dr. Jacques Neefjes (2008). "Synergizing Radiation Therapy and Immunotherapy for Curing Incurable Cancers: Opportunities and Challenges". Oncology. 22 (9): 1064–1084. PMC 3474236. PMID 18777956.{{cite journal}}: CS1 maint: multiple names: authors list (link)
9. Gina M Graziani, Jonathan B Angel (2015). "Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions". Journal of the International AIDS Society. 18 (1): 20497. doi:10.7448/IAS.18.1.20497. PMC 4641978. PMID 26561337.
10. Clinical trial number NCT01103687 for "Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults" at ClinicalTrials.gov
11. Margaret E. Gatti-Mays, Jason M. Redman, Julie M. Collins, Marijo Bilusic (2017). "Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations". Human Vaccines & Immunotherapeutics. 13 (11): 2561–2574. doi:10.1080/21645515.2017.1364322. PMC 5703410. PMID 28857666.{{cite journal}}: CS1 maint: multiple names: authors list (link)
12. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators (2010). "Sipuleucel-T immunotherapy for castration-resistant prostate cancer". New England Journal of Medicine. 363 (5): 411–22. doi:10.1056/NEJMoa1001294. PMID 20818862. S2CID 12168204.{{cite journal}}: CS1 maint: multiple names: authors list (link)
13. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS (2015). "Talimogene laherparepvec improves durable response rate in patients with advanced melanoma". Journal of Clinical Oncology. 33 (25): 2780–88. doi:10.1200/JCO.2014.58.3377. PMID 26014293. S2CID 23663167.{{cite journal}}: CS1 maint: multiple names: authors list (link)

• Cancer vaccines